Bert Klebl
Impact in
- Infectious Diseases top 2%
- Tuberculosis Research and Epidemiology
- Immunology top 5%
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
Papers in
-
- Protein Kinase Regulation and GTPase Signaling 8
-
- Computational Drug Discovery Methods 10
- Co-authors
- Anil Koul (3 shared papers)Jan Eickhoff (20 shared papers)Axel Ullrich (2 shared papers)Thomas Herget (2 shared papers)Gerhard Müller (6 shared papers)Axel Choidas (10 shared papers)Peter Habenberger (9 shared papers)Peter Nußbaumer (6 shared papers)
- Journals
- ChemMedChem (5 papers)Journal of Medicinal Chemistry (4 papers)Assay and Drug Development Technologies (3 papers)Nature (2 papers)Expert Opinion on Drug Discovery (2 papers)
- Partner nations
- GermanyNorwaySwitzerland
In The Last Decade
Bert Klebl
84 papers receiving 5.3k citations
Bert Klebl's Hit Papers
Peers
Comparison fields: 5 of 111
- Infectious Diseases 684
- Immunology 628
- Molecular Biology 2k
- Cell Biology 262
- Oncology 424
Countries citing papers authored by Bert Klebl
This map shows the geographic impact of Bert Klebl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bert Klebl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bert Klebl more than expected).
Fields of papers citing papers by Bert Klebl
This network shows the impact of papers produced by Bert Klebl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bert Klebl. The network helps show where Bert Klebl may publish in the future.
Co-authors
The 25 scholars most cited alongside Bert Klebl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 85 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer Hit paper breakdown → | 2010 | 707 |
| 2 | Gasdermin D plays a vital role in the generation of neutrophil extracellular traps Hit paper breakdown → | 2018 | 641 |
| 3 | 2004 | 486 | |
| 4 | 2014 | 389 | |
| 5 | 2004 | 314 | |
| 6 | 2000 | 211 | |
| 7 | 2005 | 208 | |
| 8 | 2020 | 201 | |
| 9 | 2012 | 188 | |
| 10 | 2017 | 166 | |
| 11 | 2004 | 121 | |
| 12 | 1998 | 117 | |
| 13 | 2013 | 105 | |
| 14 | 2008 | 99 | |
| 15 | 2015 | 95 | |
| 16 | 2008 | 75 | |
| 17 | 2008 | 73 | |
| 18 | 2014 | 69 | |
| 19 | 2008 | 66 | |
| 20 | 2018 | 59 |
About Bert Klebl
Bert Klebl is a scholar working on Molecular Biology, Computational Theory and Mathematics, Organic Chemistry, Infectious Diseases and Physiology, having authored 85 papers that have together received 5.5k indexed citations. Recurring topics across this work include Computational Drug Discovery Methods (10 papers), Protein Kinase Regulation and GTPase Signaling (8 papers), Cytomegalovirus and herpesvirus research (7 papers), Synthesis and biological activity (7 papers), Tuberculosis Research and Epidemiology (5 papers), Synthesis and Characterization of Heterocyclic Compounds (4 papers), Calcium signaling and nucleotide metabolism (4 papers) and Lung Cancer Treatments and Mutations (4 papers). The work is most often cited by research in Infectious Diseases (684 citations), Immunology (628 citations), Molecular Biology (2k citations), Cell Biology (262 citations) and Oncology (424 citations). Bert Klebl has collaborated with scholars based in Germany, Norway and Switzerland. Frequent co-authors include Anil Koul, Jan Eickhoff, Axel Ullrich, Thomas Herget, Gerhard Müller, Axel Choidas, Peter Habenberger, Peter Nußbaumer, Anne Walburger and Liem Nguyen. Their work appears in journals such as ChemMedChem, Journal of Medicinal Chemistry, Assay and Drug Development Technologies, Nature and Expert Opinion on Drug Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.